Using three independent immunotherapy datasets from the GEO database (targeting PD-1/PD-L1/CTLA-4), the study further validated that low-risk patients may serve as positive prognostic indicators for immunotherapy in HNSCC. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.